Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Nanoviricides Inc (NNVC)

Nanoviricides Inc (NNVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,385
  • Shares Outstanding, K 13,946
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,290 K
  • EBIT $ -10 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.11

Options Overview Details

View History
  • Implied Volatility 260.96% ( -26.30%)
  • Historical Volatility 53.91%
  • IV Percentile 75%
  • IV Rank 35.99%
  • IV High 652.63% on 11/18/24
  • IV Low 40.76% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 280
  • Volume Avg (30-Day) 209
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 3,224
  • Open Int (30-Day) 2,461

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +166,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +0.72%
on 01/08/25
1.6500 -15.76%
on 01/06/25
-0.1100 (-7.33%)
since 12/06/24
3-Month
1.2000 +15.83%
on 11/15/24
1.6500 -15.76%
on 01/06/25
-0.0300 (-2.11%)
since 10/08/24
52-Week
1.0100 +37.62%
on 01/23/24
3.5900 -61.28%
on 06/10/24
+0.2600 (+23.01%)
since 01/08/24

Most Recent Stories

More News
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going...

NNVC : 1.3900 (-9.15%)
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going...

NNVC : 1.3900 (-9.15%)
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential...

NNVC : 1.3900 (-9.15%)
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential...

NNVC : 1.3900 (-9.15%)
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

THAR : 2.17 (-3.02%)
ACXP : 0.7510 (-6.88%)
UBI.AX : 0.100 (unch)
GRF.VN : 0.480 (unch)
WISA : 1.9100 (-7.73%)
NNVC : 1.3900 (-9.15%)
ALCO : 29.80 (-1.13%)
MYPS : 1.7700 (-0.56%)
ABL : 7.39 (-2.25%)
PERF : 2.62 (-10.88%)
PETV : 0.9157 (+0.10%)
ABEO : 5.96 (-0.67%)
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

ESGH.TO : 29.83 (+0.40%)
THAR : 2.17 (-3.02%)
ACXP : 0.7510 (-6.88%)
GRF.VN : 0.480 (unch)
WISA : 1.9100 (-7.73%)
ALCO : 29.80 (-1.13%)
NNVC : 1.3900 (-9.15%)
ABL : 7.39 (-2.25%)
MYPS : 1.7700 (-0.56%)
PERF : 2.62 (-10.88%)
PETV : 0.9157 (+0.10%)
ABEO : 5.96 (-0.67%)
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024...

NNVC : 1.3900 (-9.15%)
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024...

NNVC : 1.3900 (-9.15%)
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END

BCRX : 8.05 (-1.11%)
NNVC : 1.3900 (-9.15%)
VERU : 0.7260 (-2.46%)
CMRX : 3.49 (-4.64%)
SIGA : 6.28 (-0.16%)
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

NNVC : 1.3900 (-9.15%)
VERU : 0.7260 (-2.46%)
CMRX : 3.49 (-4.64%)
SIGA : 6.28 (-0.16%)

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 1.6253
2nd Resistance Point 1.5743
1st Resistance Point 1.4821
Last Price 1.3900
1st Support Level 1.3389
2nd Support Level 1.2879
3rd Support Level 1.1957

See More

52-Week High 3.5900
Fibonacci 61.8% 2.6044
Fibonacci 50% 2.3000
Fibonacci 38.2% 1.9956
Last Price 1.3900
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar